Cerebrolysin

Mechanism

A mixture of low-molecular-weight neuropeptides and free amino acids reported to reproduce neurotrophic factor activity on neurons.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Stroke recovery research
• Cognitive function research
• Neurotrophic signalling context

Half-life, storage & sport

Elimination half-life

not on file — no primary pharmacokinetic study found.

Storage

Reconstituted: Solution in sealed ampoules (not lyophilized). Store below 25C, protect from light, do not freeze; single-use, use immediately once opened. — source. EVER Pharma product information.

In sport (WADA 2026)

Not prohibited. Not named, and it is an approved medicine in Austria, Russia, China and elsewhere, so S0 does not apply. It is a porcine brain peptide preparation containing neurotrophic fragments; if a batch carried growth-factor activity, S2.3's residual clause could be argued. Not FDA-approved. the list

Literature on file 10

• animal in vivo
  Neurotrophic effects of Cerebrolysin® in animal models of excitotoxicity (2000, cited 9x) graded on: an animal model — read from the indexed abstract — “mice”
• human observational
  Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. graded on: a synthesis of human studies — “Systematic Review”
• in vitro
  Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability. graded on: an in-vitro system — read from the indexed abstract — “in vitro”
• human RCT
  NCT00947531: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia graded on: randomised and placebo-controlled — “Randomized, Double-blind, Placebo-controlled”
• human RCT
  NCT00911807: A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD) graded on: a randomised trial — “Randomized, Double-Blind, Clinical Trial”
• human RCT
  NCT02149875: A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study. graded on: a randomised study — “Randomized, Double-blind Study”
• human RCT
  Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial (Stroke 2016, cited 120x) graded on: randomised and placebo-controlled — “Randomized, Placebo-Controlled”
• human observational
  Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials (Neurological Sciences 2017, cited 102x) graded on: a synthesis of human studies — “meta-analysis”

Not graded

2 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  NCT00840671: A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke graded on: NCT00840671 is completed and has posted no results - a registration, not a reported outcome — “NCT00840671”
• not graded
  NCT01388738: Navigation Brain Stimulation (NBS) for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke. graded on: NCT01388738 is completed and has posted no results - a registration, not a reported outcome — “NCT01388738”

What is circulated not evidence 6

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose ubiquitous nothing on file either way

  5 to 10 mL a day for cognitive enhancement in healthy people is the community protocol, typically five days on and two days off for four to eight weeks then a four-week break.

  5 days on, 2 days off for 4–8 weeks, then 4-week break

  On the record The record holds no dosing at all for cerebrolysin. No dose, no volume and no cycle is on file for a compound that is a licensed medicine in several countries with a published ampoule strength, and which the record itself grades at the human randomised-trial rung.

  Source 1 · Source 2

• unverified community data dose common nothing on file either way

  Subcutaneous self-injection is described in nootropic guides as the most accessible route, while the trials the compound's reputation rests on used intravenous infusion under supervision.

  Subcutaneous (most accessible)

  On the record The record lists two route entries — intravenous or intramuscular, and subcutaneous, intramuscular or intranasal — with nothing distinguishing which carries the trial evidence. It grades the compound at the human randomised-trial rung on 'randomised and placebo-controlled' without saying by which route, so it cannot answer the question the community is answering with guesswork.

  Source 1

• unverified community data side effect common nothing on file either way

  Vivid dreams are described in guides as normal and as a sign of neuroplasticity, and early headaches as expected and self-resolving.

  vivid dreams (normal, sign of neuroplasticity activity)

  On the record The record holds no side effects at all for cerebrolysin. An effect is being interpreted as evidence that the compound is working, against a safety record that holds nothing.

  Source 1

• unverified community data benefit common contradicts the record

  The safety record established in thousands of stroke patients in controlled trials is transferred in community copy to healthy users at biohacking doses.

  5–10mL of pharmaceutical ampoule solution per day

  On the record The record lists stroke recovery research, cognitive function research and neurotrophic signalling context as benefits — all indication-shaped, none about healthy cognitive enhancement. Its list of fields not on file is unusually long — molecular weight, formula, CAS number, PubChem entry, structure identifiers and half-life are all not held — and it notes the record was merged from two prior entries and never graded as a whole.

  Source 1 · Source 2

• unverified community data dose occasional nothing on file either way

  Ten millilitres a day is stated as the minimum effective dose for a statistically significant cognitive effect, with 5 mL said to have failed significance and 30 mL to add nothing.

  5–10mL of pharmaceutical ampoule solution per day

  On the record Not on file. The record holds no dose-response data and no dose at all for cerebrolysin, so a specific claim about which volumes reached significance cannot be checked against it.

  Source 1 · Source 2

• unverified community data storage occasional contradicts the record

  Ampoules are described as being stored and handled like any other peptide vial, with the solution kept for repeated use across a course.

  Injection site irritation is possible

  On the record The record is explicit and contradicts this: solution in sealed ampoules, not lyophilised; store below 25C, protect from light, do not freeze; single-use, use immediately once opened. The single-use instruction is one of the clearer safety-relevant facts in this slice, and it is not what the community practice assumes.

  Source 1

Identity

Also called

• Cerebralisin

Listed prices 31

What 26 shops we track listed for Cerebrolysin, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.